Objective
to evaluate the clinical efficacy of T-TEER plus optimised medical treatment (OMT) vs. OMT alone in patients with tricuspid regurgitation
Study
investigator-initiated prospective multivessel randomised trial
Population
patients with severe, symptomatic tricuspid regurgitation
Endpoints
composite of change in NYHA class, change in global assessment or occurrence of MACE at 1 year
Conclusion
T-TEER improves a composite-driven clinical score at 1 year compared to OMT in patients with severe tricuspid regurgitation.
Donal et al. JAMA. 2025;333(2):124-132